Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, JaeHyoung | - |
dc.contributor.author | Ko, Young-Hoon | - |
dc.contributor.author | Joe, Sook-Haeng | - |
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Lee, Moon-Soo | - |
dc.contributor.author | Yang, Jaewon | - |
dc.date.accessioned | 2021-09-07T05:18:59Z | - |
dc.date.available | 2021-09-07T05:18:59Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2011-12-01 | - |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/110932 | - |
dc.description.abstract | This study examined the long-term effectiveness and tolerability of zonisamide for weight control in psychiatric outpatients using various psychotropic medications. We conducted a systematic chart review of 82 psychiatric outpatients with unwanted weight gain after the introduction of psychotropic drugs between January 2008 and September 2009 at Korea University Ansan Hospital. The primary outcome measure was the effect of zonisamide on body mass index (BMI). Additional outcome measures included safety and tolerability as assessed by the clinical global impression-severity of illness scale (CGI-S) and discontinuation rate. The mean final dose of zonisamide was 124.6 +/- 53.4 mg/day and ranged from 50 mg/day to 300 mg/day. The mean BMI reduction was 0.8 +/- 1.7 kg/m(2) and ranged from -2.9 kg/m(2) to 4.7 kg/m(2) (p<0.001). We also observed a significant reduction in CGI-S scores from the baseline (3.8 +/- 0.9) to the endpoint (3.3 +/- 0.8; p<0.001). Twelve patients (14.6%) discontinued their zonisamide treatment due to its side effects. Patients treated with zonisamide showed significant weight loss. Furthermore, its treatment was generally safe and well tolerated with few negative effects on patients' overall psychiatric symptoms. Additional research is required to confirm these results and to investigate whether patients have rebound weight gains after discontinuing zonisamide. (C) 2011 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject | BIPOLAR DISORDER | - |
dc.subject | ADJUNCTIVE ZONISAMIDE | - |
dc.subject | MEDICATIONS | - |
dc.subject | MANAGEMENT | - |
dc.subject | MIGRAINE | - |
dc.subject | OBESITY | - |
dc.subject | GAIN | - |
dc.title | Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ko, Young-Hoon | - |
dc.contributor.affiliatedAuthor | Joe, Sook-Haeng | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.contributor.affiliatedAuthor | Lee, Moon-Soo | - |
dc.identifier.doi | 10.1016/j.pnpbp.2011.07.007 | - |
dc.identifier.scopusid | 2-s2.0-82455212951 | - |
dc.identifier.wosid | 000297831900018 | - |
dc.identifier.bibliographicCitation | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.35, no.8, pp.1918 - 1921 | - |
dc.relation.isPartOf | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.title | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.volume | 35 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1918 | - |
dc.citation.endPage | 1921 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | BIPOLAR DISORDER | - |
dc.subject.keywordPlus | ADJUNCTIVE ZONISAMIDE | - |
dc.subject.keywordPlus | MEDICATIONS | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | MIGRAINE | - |
dc.subject.keywordPlus | OBESITY | - |
dc.subject.keywordPlus | GAIN | - |
dc.subject.keywordAuthor | Obesity | - |
dc.subject.keywordAuthor | Psychotropic drugs | - |
dc.subject.keywordAuthor | Weight | - |
dc.subject.keywordAuthor | Zonisamide | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.